JPH10500123A - アミノスルホン酸の誘導体、プソイドペプチドの合成における同誘導体の利用、およびその製造法 - Google Patents
アミノスルホン酸の誘導体、プソイドペプチドの合成における同誘導体の利用、およびその製造法Info
- Publication number
- JPH10500123A JPH10500123A JP7529348A JP52934895A JPH10500123A JP H10500123 A JPH10500123 A JP H10500123A JP 7529348 A JP7529348 A JP 7529348A JP 52934895 A JP52934895 A JP 52934895A JP H10500123 A JPH10500123 A JP H10500123A
- Authority
- JP
- Japan
- Prior art keywords
- pseudopeptide
- acid
- bond
- derivative
- equal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 25
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 20
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 title claims description 31
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 150000001413 amino acids Chemical class 0.000 claims abstract description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 29
- 239000001257 hydrogen Substances 0.000 claims abstract description 28
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 20
- 150000003839 salts Chemical group 0.000 claims abstract description 19
- 150000001412 amines Chemical class 0.000 claims abstract description 17
- 125000003277 amino group Chemical group 0.000 claims abstract description 17
- 125000003118 aryl group Chemical group 0.000 claims abstract description 13
- 239000012634 fragment Substances 0.000 claims abstract description 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 10
- 125000006239 protecting group Chemical group 0.000 claims abstract description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 55
- 235000001014 amino acid Nutrition 0.000 claims description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 229940124530 sulfonamide Drugs 0.000 claims description 20
- 150000008054 sulfonate salts Chemical class 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 235000018102 proteins Nutrition 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 8
- 230000004224 protection Effects 0.000 claims description 8
- 150000003459 sulfonic acid esters Chemical class 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 claims description 4
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 3
- 239000004593 Epoxy Substances 0.000 claims description 3
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 3
- 150000001371 alpha-amino acids Chemical class 0.000 claims description 3
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- DQPBABKTKYNPMH-UHFFFAOYSA-M amino sulfate Chemical class NOS([O-])(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-M 0.000 claims description 2
- 230000002452 interceptive effect Effects 0.000 claims description 2
- 125000000565 sulfonamide group Chemical group 0.000 claims description 2
- 150000003457 sulfones Chemical class 0.000 claims description 2
- PSDYQSWHANEKRV-UHFFFAOYSA-N [S]N Chemical compound [S]N PSDYQSWHANEKRV-UHFFFAOYSA-N 0.000 claims 2
- 150000003460 sulfonic acids Chemical class 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 10
- 125000006165 cyclic alkyl group Chemical group 0.000 abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 28
- 150000001875 compounds Chemical class 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 12
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- 230000000144 pharmacologic effect Effects 0.000 description 10
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- -1 ketomethylene Chemical group 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 238000009740 moulding (composite fabrication) Methods 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 150000003456 sulfonamides Chemical class 0.000 description 4
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 4
- BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- OOQRRYDVICNJGC-MRVPVSSYSA-N tert-butyl n-[(2s)-1-hydroxy-3-methylbutan-2-yl]carbamate Chemical compound CC(C)[C@@H](CO)NC(=O)OC(C)(C)C OOQRRYDVICNJGC-MRVPVSSYSA-N 0.000 description 3
- OEQRZPWMXXJEKU-LURJTMIESA-N tert-butyl n-[(2s)-1-oxopropan-2-yl]carbamate Chemical compound O=C[C@H](C)NC(=O)OC(C)(C)C OEQRZPWMXXJEKU-LURJTMIESA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 2
- 230000002686 anti-diuretic effect Effects 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical class C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 201000010064 diabetes insipidus Diseases 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 125000003700 epoxy group Chemical group 0.000 description 2
- PCUFRDPZBYBMLL-UHFFFAOYSA-N ethyl diethylphosphorylmethanesulfonate Chemical compound CCOS(=O)(=O)CP(=O)(CC)CC PCUFRDPZBYBMLL-UHFFFAOYSA-N 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- YDBPZCVWPFMBDH-QMMMGPOBSA-N tert-butyl (2s)-2-formylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C=O YDBPZCVWPFMBDH-QMMMGPOBSA-N 0.000 description 2
- PDAFIZPRSXHMCO-LURJTMIESA-N tert-butyl n-[(2s)-1-hydroxypropan-2-yl]carbamate Chemical compound OC[C@H](C)NC(=O)OC(C)(C)C PDAFIZPRSXHMCO-LURJTMIESA-N 0.000 description 2
- YMNBXYLOSIKZGL-MRVPVSSYSA-N tert-butyl n-[(2s)-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound CC(C)[C@@H](C=O)NC(=O)OC(C)(C)C YMNBXYLOSIKZGL-MRVPVSSYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- NWYYWIJOWOLJNR-UHFFFAOYSA-N 2-Amino-3-methyl-1-butanol Chemical compound CC(C)C(N)CO NWYYWIJOWOLJNR-UHFFFAOYSA-N 0.000 description 1
- QPMCUNAXNMSGTK-UHFFFAOYSA-N 2-aminopropanal Chemical class CC(N)C=O QPMCUNAXNMSGTK-UHFFFAOYSA-N 0.000 description 1
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 1
- 241001598984 Bromius obscurus Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 229930182579 Cyclotheonamide Natural products 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 239000003160 antidiuretic agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229930182852 proteinogenic amino acid Natural products 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- BFFLLBPMZCIGRM-QMMMGPOBSA-N tert-butyl (2s)-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CO BFFLLBPMZCIGRM-QMMMGPOBSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/69—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a carbon skeleton substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. アミノスルホン酸の誘導体であって、下記の一般式を有することを特徴 とする誘導体。 (式中、 Rは、水素、天然アミノ酸の側鎖、置換または未置換の線状、分岐状または環状 アルキル鎖、アリールアルキル鎖、アリールおよびヘテロ芳香族性基に相当する フラグメントから選択され、 Yは水素を表し、この場合には相当するアミンの可能な塩形態、またはアミン基 の保護に普通に用いられる任意の保護基を包含し、 XはCl、OH、OCH2CH3、OCH3、ONBu4、NHCH2Phを表す。 ) 2. Rが−CH3に等しく選択され、Yが(CH3)3C−OCO−保護基に 等しく選択され、XがClに等しく選択される、請求の範囲第1項に記載のアミ ノスルホン酸の誘導体。 3. Yが(CH3)3C−OCO−保護基に等しく選択され、RがCH3に等 しく選択され、XがONBu4に等しく選択される、請求の範囲第1項に記載の アミノスルホン酸の誘導体。 4. Yは水素に等しく選択され、上記の相当するアミンが塩酸塩の形態を有 し、RがCH3に等しく選択され、XがOCH2CH3に等しく選択される、請求 の範囲第1項に記載のアミノスルホン酸の誘導体。 5. Rがタンパク生成アミノ酸の側鎖から選択され、Yが(CH3)3C− OCO−保護基に等しく、XがOR1に等しく、但しR1は−CH3および−CH2 CH3から選択され、下記の式を有する、請求の範囲第1項に記載のアミノスル ホン酸の誘導体。 6. RがCH3に等しく、R1が−CH2CH3に等しい、請求の範囲第5項に 記載のアミノスルホン酸の誘導体。 7. Rが(CH3)2CH−に等しく、R1が−CH2CH3に等しい、請求の 範囲第5項に記載のアミノスルホン酸の誘導体。 8. RがCH3に等しく、R1が−CH3に等しい、請求の範囲第5項に記載 のアミノスルホン酸の誘導体。 9. α−β位においてエポキシ基またはシクロプロパン基が挿入されて二重 結合が官能化されている、請求の範囲第1項に記載のアミノスルホン酸の誘導体 。 10. シントンとしてプソイドペプチドの合成に用いられる、請求の範囲第 1項に記載のアミノスルホン酸の誘導体。 11. 二重結合に共役する少なくとも1つのスルホンアミド型結合を有する 、請求の範囲第10項に記載のシントンを用いて得たプソイドペプチド。 12. 下記の式を有する請求の範囲第11項に記載のプソイドペプチド。 (式中、R2は水素、天然アミノ酸の側鎖、置換または未置換の線状、分岐状ま たは環状アルキル鎖、アリールアルキル鎖、アリールおよびヘテロ芳香族性基に 相当するフラグメントから選択され、Rと等しいかまたは異なる。) 13. Yが(CH3)3C−OCO−保護基と等しく、RがR2と等しくCH3 と等しく、XがNHCH2Phと等しい、請求の範囲第12項に記載のプソイド ペプチド。 14. Yが(CH3)3C−OCO−保護基と等しく、RがR2と等しくかつ CH3と等しく、Xが−OCH2CH3と等しい、請求の範囲第12項に記載のプ ソイドペプチド。 15. Yが(CH3)3C−OCO−保護基と等しく、RがCH3であり、R2 が(CH3)2CH−であり、Xが−OCH2CH3と等しい、請求の範囲第12項 に記載のプソイドペプチド。 16. スルホンアミド基と比較してα−β位で少なくとも1つの二重結合に 官能化され、エポキシまたはシクロプロパン基を与える、請求の範囲第11項に 記載のプソイドペプチド。 17. 請求の範囲第1項に記載のスルホン酸性アミノ酸の誘導体の製造法で あって、下記の工程を含んでなる、方法。 天然のα−アミノ酸をα−アミノアルデヒドに転換し、 上記α−アミノアルデヒドを、Wittig-Horner 反応によって上記アミノスルホ ン酸の誘導体に転換する。 18. 上記の天然のα−アミノ酸が(L)型または(D)型のタンパク形成 アミノ酸である、請求の範囲第17項に記載のアミノスルホン酸の誘導体の製造 法。 19. 請求の範囲第11項に記載のプソイドペプチドの製造法であって、下 記の工程を含んでなる方法。 (I)から誘導されたγ−アミノ−α,β−不飽和スルホン酸エステルの相当す るスルホネート塩への転換、 上記スルホネート塩を活性化することによる活性化したスルホネート塩の生成 、 上記活性化したスルホネート塩と好適に活性化してアミン基としたアミノスル ホン酸の誘導体(I)の結合、 によるスルホンアミド結合を有するプソイドペプチドの生成。 20. 請求の範囲第12項に記載の前記プソイドペプチドを、交互にアミン 基またはスルホン酸基の放出および活性化を行ない、更に、適当に活性化した(I )と結合させて、このやり方で相互作用型の方法を実現し、スルホンアミド結合 を有するプソイドペプチドを生成させることを特徴とする、プソイドペプチドの 製造法。 21. 請求の範囲第11項に記載のプソイドペプチドの製造法であって、下 記の工程を含んでなる方法。 (I)から誘導されたγ−アミノ−α,β−不飽和スルホン酸エステルの相当す るスルホン化塩への転換、 上記のスルホン化塩の活性化による、活性化したスルホン化塩の生成、 上記活性化したスルホン化塩と適当に活性化した天然アミノ酸との結合、 によるスルホンアミド結合を有し少なくとも1つの遊離の、保護された、塩形成 した、または活性化したカルボキシル基を有するプソイドペプチドの生成。 22. プソイドペプチドの製造法であって、請求の範囲第21項に記載のプ ソイドペプチドを、交互にアミン基またはカルボキシル基の放出および活性化を 行ない、更に、天然アミノ酸または適当に活性化した(I)と結合させて、このや り方で相互作用型の方法を実現し少なくとも1つのスルホンアミド結合を有する プソイドペプチドを生成させることを特徴とする、方法。 23. 下記の化学式を有する、請求の範囲第1項に記載のアミノスルホン酸 の誘導体。 24. 下記の化学式を有する、請求の範囲第1項に記載のアミノスルホン酸 の誘導体。 25. 請求の範囲第11項に記載の二重結合に共役する少なくとも1つのス ルホンアミド型結合を有するプソイドペプチドであって、下記の化学式を有する プソイドペプチド。 26. 請求の範囲第11項に記載の二重結合に共役する少なくとも1つのス ルホンアミド型結合を有するプソイドペプチドであって、下記の化学式を有する プソイドペプチド。 27. 請求の範囲第21項に記載の方法に従って得られる二重結合に共役す る少なくとも1つのスルホンアミド型結合を有するプソイドペプチドであって、 下記の化学式を有するプソイドペプチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT94A000989 | 1994-05-17 | ||
ITMI940989A IT1269511B (it) | 1994-05-17 | 1994-05-17 | Derivati di acidi ammino-solfonici , loro impiego nella sintesi di pseudopeptidi e procedimento per la loro preparazione |
PCT/EP1995/001788 WO1995031433A1 (en) | 1994-05-17 | 1995-05-11 | Derivatives of aminosulfonic acids, utilization of the same in the synthesis of pseudopeptides and process for their preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10500123A true JPH10500123A (ja) | 1998-01-06 |
JP4023554B2 JP4023554B2 (ja) | 2007-12-19 |
Family
ID=11368917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52934895A Expired - Fee Related JP4023554B2 (ja) | 1994-05-17 | 1995-05-11 | アミノスルホン酸の誘導体、プソイドペプチドの合成における同誘導体の利用、およびその製造法 |
Country Status (17)
Country | Link |
---|---|
US (1) | US5869725A (ja) |
EP (1) | EP0759902B1 (ja) |
JP (1) | JP4023554B2 (ja) |
KR (1) | KR970703307A (ja) |
CN (1) | CN1148847A (ja) |
AT (1) | ATE174329T1 (ja) |
AU (1) | AU691292B2 (ja) |
CA (1) | CA2189896A1 (ja) |
DE (1) | DE69506540T2 (ja) |
ES (1) | ES2125617T3 (ja) |
FI (1) | FI964582A0 (ja) |
HU (1) | HUT76483A (ja) |
IT (1) | IT1269511B (ja) |
NO (1) | NO964861L (ja) |
NZ (1) | NZ285763A (ja) |
PL (1) | PL317258A1 (ja) |
WO (1) | WO1995031433A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214799B1 (en) | 1996-05-14 | 2001-04-10 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
US6020371A (en) * | 1997-03-28 | 2000-02-01 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds compositions containing them and methods for their use |
US6331554B1 (en) | 1997-03-28 | 2001-12-18 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds, compositions containing them, and methods for their use |
US5962487A (en) * | 1997-12-16 | 1999-10-05 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
CN1198838C (zh) | 1998-04-30 | 2005-04-27 | 阿格罗尼制药公司 | 抗小rna病毒化合物及其制备方法和用途 |
JP2002516904A (ja) | 1998-06-03 | 2002-06-11 | ジーピーアイ ニル ホールディングス インコーポレイテッド | N−複素環式カルボン酸またはカルボン酸等配電子体のn−結合スルホンアミド |
US6358928B1 (en) | 1999-11-22 | 2002-03-19 | Enzyme Systems Products | Peptidyl sulfonyl imidazolides as selective inhibitors of serine proteases |
PA8507801A1 (es) | 1999-12-03 | 2002-08-26 | Agouron Pharma | Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y los materiales para su sintesis |
PE20011277A1 (es) | 2000-04-14 | 2002-01-07 | Agouron Pharma | Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y los materiales para su sintesis |
PL365470A1 (en) | 2000-06-14 | 2005-01-10 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
JPWO2002074299A1 (ja) * | 2000-12-27 | 2004-07-08 | 味の素株式会社 | TNFα産生抑制剤 |
-
1994
- 1994-05-17 IT ITMI940989A patent/IT1269511B/it active IP Right Grant
-
1995
- 1995-05-11 KR KR1019960706501A patent/KR970703307A/ko not_active Application Discontinuation
- 1995-05-11 PL PL95317258A patent/PL317258A1/xx unknown
- 1995-05-11 CA CA002189896A patent/CA2189896A1/en not_active Abandoned
- 1995-05-11 WO PCT/EP1995/001788 patent/WO1995031433A1/en active IP Right Grant
- 1995-05-11 DE DE69506540T patent/DE69506540T2/de not_active Expired - Fee Related
- 1995-05-11 JP JP52934895A patent/JP4023554B2/ja not_active Expired - Fee Related
- 1995-05-11 AT AT95919441T patent/ATE174329T1/de not_active IP Right Cessation
- 1995-05-11 NZ NZ285763A patent/NZ285763A/en unknown
- 1995-05-11 ES ES95919441T patent/ES2125617T3/es not_active Expired - Lifetime
- 1995-05-11 EP EP95919441A patent/EP0759902B1/en not_active Expired - Lifetime
- 1995-05-11 CN CN95193138A patent/CN1148847A/zh active Pending
- 1995-05-11 AU AU25268/95A patent/AU691292B2/en not_active Expired - Fee Related
- 1995-05-11 US US08/737,379 patent/US5869725A/en not_active Expired - Fee Related
- 1995-05-11 HU HU9603128A patent/HUT76483A/hu unknown
-
1996
- 1996-11-15 NO NO964861A patent/NO964861L/no unknown
- 1996-11-15 FI FI964582A patent/FI964582A0/fi not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0759902A1 (en) | 1997-03-05 |
CA2189896A1 (en) | 1995-11-23 |
ITMI940989A0 (it) | 1994-05-17 |
ES2125617T3 (es) | 1999-03-01 |
FI964582A (fi) | 1996-11-15 |
WO1995031433A1 (en) | 1995-11-23 |
NZ285763A (en) | 1997-10-24 |
AU691292B2 (en) | 1998-05-14 |
ATE174329T1 (de) | 1998-12-15 |
US5869725A (en) | 1999-02-09 |
IT1269511B (it) | 1997-04-01 |
AU2526895A (en) | 1995-12-05 |
MX9605426A (es) | 1998-05-31 |
HUT76483A (en) | 1997-09-29 |
HU9603128D0 (en) | 1997-01-28 |
DE69506540T2 (de) | 1999-06-02 |
EP0759902B1 (en) | 1998-12-09 |
ITMI940989A1 (it) | 1995-11-17 |
FI964582A0 (fi) | 1996-11-15 |
KR970703307A (ko) | 1997-07-03 |
JP4023554B2 (ja) | 2007-12-19 |
NO964861L (no) | 1997-01-16 |
PL317258A1 (en) | 1997-04-01 |
NO964861D0 (no) | 1996-11-15 |
DE69506540D1 (de) | 1999-01-21 |
CN1148847A (zh) | 1997-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3509029B2 (ja) | 生物活性環化ポリペプチド | |
US4732890A (en) | Retro-inverso hexapeptide neurotensin analogs, process for their preparation and pharmaceutical compositions containing them | |
JP2540534B2 (ja) | オリゴペプチジルニトリル誘導体 | |
SK63194A3 (en) | Peptide derivatives | |
FR2609289A1 (fr) | Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes | |
IE60128B1 (en) | Hydroxylamine derivatives,their preparation and use as medicaments | |
EP0253190B1 (en) | Partially retro-inverted tuftsin analogues, method for the preparation thereof and pharmaceutical compositions containing them | |
KR20120034642A (ko) | 펩티드 및 펩티드?관련 화합물의 고침투성 전구약물 조성물 | |
JP4023554B2 (ja) | アミノスルホン酸の誘導体、プソイドペプチドの合成における同誘導体の利用、およびその製造法 | |
CH635571A5 (fr) | Tetrapeptides et composition therapeutique les contenant. | |
JP5433586B2 (ja) | ペプチド修飾の方法 | |
US6376649B1 (en) | Methods for the synthesis of α- hydroxy-β-amino acid and amide derivatives | |
JPS61155396A (ja) | ニユーロテンシン様ペプチド及びその製法 | |
JPH11509850A (ja) | ドラスタチン15の製法及びその中間体 | |
US3948971A (en) | N-protected-α-amino acid compounds | |
JPH02209865A (ja) | 3―チオプロピオン酸誘導体の製造法 | |
JPH07316193A (ja) | ペプチド誘導体およびその用途 | |
EP1440977B1 (fr) | Procédé de synthèse amélioré de dérivés diamides du tripeptide KPV | |
FR2654430A1 (fr) | Nouveaux derives de peptides, utilisables comme inhibiteurs des collagenases bacteriennes. | |
MXPA96005426A (en) | Derivatives of aminosulphonic acids, use of them in the synthesis of pseudopeptides and procedure for preparation | |
JPH02273696A (ja) | ペプチドおよびこれを含有する抗痴呆剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051206 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060306 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060829 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061129 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070629 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070828 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070926 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101012 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |